Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.69 | N/A | +13.33% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $4.69 | N/A | +13.33% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering innovative therapies.
The earnings report shows that United Therapeutics exceeded EPS expectations, which likely contributed to the positive stock reaction of 3.36%. Investors may view the strong EPS as a sign of the company's financial health, even in the absence of revenue data and guidance. The management's cautious optimism suggests they are focused on future growth while navigating current market conditions.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STATE STR CORP
Oct 23, 2017